Last reviewed · How we verify
FOFLOX4
FOFLOX4 is a chemotherapy regimen combining fluorouracil, folinic acid (leucovorin), and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
FOFLOX4 is a chemotherapy regimen combining fluorouracil, folinic acid (leucovorin), and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Colorectal cancer (metastatic or locally advanced), Gastric cancer, Pancreatic cancer.
At a glance
| Generic name | FOFLOX4 |
|---|---|
| Sponsor | Guangdong Provincial People's Hospital |
| Drug class | Combination chemotherapy regimen |
| Target | Thymidylate synthase (5-FU); DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOFLOX4 is a combination chemotherapy regimen where 5-fluorouracil (5-FU) inhibits thymidylate synthase to disrupt DNA synthesis, folinic acid enhances 5-FU efficacy by stabilizing its binding to the enzyme, and oxaliplatin forms DNA cross-links to prevent replication. This triple-agent approach targets rapidly dividing cancer cells through multiple mechanisms of cytotoxicity.
Approved indications
- Colorectal cancer (metastatic or locally advanced)
- Gastric cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Peripheral neuropathy
- Anemia
- Mucositis
- Thrombocytopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOFLOX4 CI brief — competitive landscape report
- FOFLOX4 updates RSS · CI watch RSS
- Guangdong Provincial People's Hospital portfolio CI